August 22-23 2018 - Outsourced Pharma- San Diego California
Case Study: Inside A (Small) Drug Sponsor - (Big) CDMO Relationship
Dr. Sandra Dunn, founder and CEO of Phoenix Molecular Designs, and members of her senior leadership team, presented a detailed case study and insight into her virtual biotech’s working relationship with CDMO WuXi (San Diego operations), and toxicology service provider Paracelsus, Inc.
“As breast cancer is the #1 cause of death in women world-wide it is a global problem that requires a global solution. This is why our strategy is to outsource several aspects of our drug development so that we have the opportunity to work with the best and brightest, leveraging years of deep industry experience to catalyze our path to commercialization.Each day women are dying of this terrible disease and working with a highly efficient outsourced team shortens our development time so that we are able to get new medicine to patients sooner” - Dr. Sandra Dunn, CEO and ~30 year veteran breast cancer researcher.
May 24, 2018 - In this all San Diego panel of three companies, Dr. Sandra Dunn, founder and CEO of Phoenix Molecular Designs, and members of her senior leadership team will present a detailed case study and insight into her virtual biotechnology company’s working relationship with CDMO WuXi (San Diego operations) and toxicology service provider Paracelsus, Inc. on August 22, 2018.
For the complete agenda for this session “Navigating an Ocean of Drug Development & Manufacturing Outsourcing” click here
April 20, 2018 - A very productive first IND planning meeting with the PhoenixMD pre-clinical and clinical operations teams was held last Friday at our JLabs location in San Diego.
Pictured are our clinical operations division Dr. Erik Flahive, Dr. Gerrit Los, Dr. Grace Furman and Dr. Terry Rugg (pictured left to right). Our CEO Dr. Sandra Dunn was on site to discuss our plans forward towards a successful filing with the FDA.
VANCOUVER, British Columbia and SAN DIEGO, April 16, 2018 - Phoenix Molecular Designs have entered into a collaboration with STA Pharmaceutical Co., Ltd (STA), a WuXi AppTec group company, to manufacture the PMD-026 needed for IND-enabling toxicology studies and a Phase I study.
Read the full press release here
January 9, 2018 - Dr. Sandra Dunn joined 500+ companies at the annual Redefining Early Stage Investments (RESI) conference in San Francisco, one of the most important investor events in the Biotech calendar. She was also invited to attend the WuXi Global Forum, to hear from the industry thought leaders about their thoughts on the rapidly changing landscape of the Biotech industry.
March 1, 2018 - Our CSO Dr. Gerrit Los attended the 2018 premier partnering event of the year, the 8th annual BIOCOM Global Life Science Partnering Conference in La Jolla, California. This conference was an exclusive forum to showcase our work to wide range of investors.
July 17, 2017 - Leading expert in Oncology, Pharmacology and Translational Medicine, Dr. Gerrit Los has been appointed as our new Chief Scientific Officer. With his expertise and guidance, PhoenixMD is advancing our program to bring our RSK kinase inhibitors to the clinic to treat the most devastating of breast cancers, Triple Negative Breast Cancer. Read the full press release here
June 23, 2017 - The mayor of San Diego, Kevin Faulconer and a trade mission of 26 delegates is visiting the Phoenix Molecular Designs head office to announce our expansion into the US. By expanding our operations into San Diego, PhoenixMD will have access to more talent in drug development, helping to accelerate the development of our TNBC treatment. Read the full press release here
May 25, 2017 - VANCOUVER, British Columbia and SAN DIEGO. Phoenix Molecular Design's latest preclinical study results show that their lead compound PMD-026 demonstrates 70% inhibition of ribosomal S6 kinase (RSK) signaling, blocking TNBC tumor growth and with no adverse effects in mice.
Read the full press release here
April 26 2017 - Hot off the press is Life Sciences BC's annual publication featuring an article on the personal story behind Phoenix Molecular Designs from our founder and CEO, Dr. Sandra Dunn. Read about our work (page 16) and a range of other inspiring women leaders in British Columbia's burgeoning Biotech industry here
March 06, 2017 - PhoenixMD is proud to be one of ten companies chosen to attend this outstanding one-of-a-kind event last week. This was an amazing opportunity for our CEO Dr. Sandra Dunn to showcase our accomplishments and to explore possibilities for partnership with some of the biggest players in the industry.
Thank you to the the Canadian Trade Commissioner Service and Consulate General of Canada in LA for their support and for promoting Phoenix at this event. Many thanks also to Dr. Dan Zekzer for being a wonderful coach.
JANUARY 16, 2017 - Phoenix Molecular Designs was selected to participate in Biocom's Global Life Science Partnering Conference 2017, which will be held on March 1-2, 2017. Our CEO Dr. Sandra Dunn will be in attendance to showcase our important work to fight Breast Cancer.
Biocom's Global Life Science Partnering Conference is an exclusive global partnering and networking forum that brings together senior executives and business development professionals from leading pharmaceutical and biotech companies. The conference includes case study presentations, individual company presentations, one-one-one meetings, and numerous networking opportunities.
The 10 companies best suited to pitch to prospective pharmaceutical partners will receive free admission (a $2000 USD value), as well as coaching and mentoring from an MNE experienced consultant in advance of the Conference. They are looking for drug development biotech firms that have game changing technologies targeting an unmet medical need, with secure IP, eye-popping data, and completed animal studies towards Proof-of-Concept and/or Phase 1 Human Clinical trials. The participating companies will have the unique opportunity to engage in the San Diego BIOCOM Coaching and Mentoring Program.
The Consulate of Canada in San Diego with support from IRAP and ISED is currently recruiting companies interested in receiving coaching and mentoring in advance of the BIOCOM Global Pharma Partnering Conference which is held on March 1-2, 2017. PhoenixMD is one of the 10 companies selected in this years competition based on their competitive edge and their ability to meet the stringent requirements for the Program.
For more information about Biocom and/or the 2017 Global Life Science Partnering Conference visit www.biocom.org
December 16, 2016 - Dr. Sandra Dunn, Founder and CEO of PhoenixMD, is featured in Richmond News sharing her passion for research and her dedication to finding new therapies for breast cancer.
We are happy to have the support of Richmond News in this thriving community.
Read the full article here
December 13, 2016 - PhoenixMD Advances into Top 10 of Small Business BC Award for Innovation of the Year 2016 and we could not be more thrilled! We would like to thank everyone who voted for us, as well as Small Business BC for giving us this amazing opportunity.
Stay tuned for updates!
Take a look at all the Top 10 Finalists of all Categories here.
November 25, 2016 - PhoenixMD was humbled at the chance to invite the Honorable Linda Reid, MLA: East Richmond, to the PhoenixMD labs in Richmond. Linda has been in office since 1991 and has continued to represent Richmond East ever since - making her the longest serving MLA in the current parliament!
We are happy to call Linda our friend and are proud to have her support for the work we are doing at PhoenixMD. Here are some pictures of her visit.
November 8, 2016 - It is with great pleasure to announce the selection of PhoenixMD for the Canadian Technology Accelerator (CTA) program in Silicon Valley, California. The CTA San Francisco program gives Canadian companies the opportunity to gain global recognition and insight into the competitive life science market. San Francisco/Silicon Valley is home to one of the largest life science hubs and markets in the U.S. which grants unparalleled access to global multi-nationals, investors and venture financers. PhoenixMD was selected among hundreds of Canadian companies to go to California to access the resources required to accelerate our growth in the U.S. and the world! PhoenixMD will have the opportunity to be introduced to the U.S./Global market, Fortune 500 companies, investors and strategic partners.
The acceptance into the CTA program will bring PhoenixMD one step close to finding a cure for cancer.
October 5/6, 2016 - Dr. Aarthi Jayanthan and Dr. My-my Huynh were fortunate to attend the 6th Annual Outsourcing in Clinical Trials Canada 2016 (AOCTC) at the Westin Wall Center in Vancouver, BC. The two-day conference focused on the best strategies used to optimize clinical trials and the various methods used to deal with difficulties that may be encountered along the way. The AOCTC was very informative and will give PhoenixMD a starting edge when planning and performing optimal clinical trial operations. Troubleshooting strategies were also discussed which will also allow PhoenixMD to outsource clinical trials in a time efficient manner.
To learn more about the Annual Outsourcing in Clinical Trials Canada click here